@article{TCR21488,
author = {Jie Peng and Lu-Shan Xiao and Zhong-Yi Dong and Wen-Wen Li and Kun-Yuan Wang and De-Hua Wu and Li Liu},
title = {Potential predictive value of JAK2 expression for Pan-cancer response to PD-1 blockade immunotherapy},
journal = {Translational Cancer Research},
volume = {7},
number = {3},
year = {2018},
keywords = {},
abstract = {Background: Recent clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1) signaling in malignant tumors. However, reliable biomarkers for predicting who would benefit from anti-PD-1/PD-L1 inhibitors have not been fully elucidated.
Methods: Here, patients from The Cancer Genome Atlas Pan-Cancer database (N=9,315) were classified into three groups based on the tri-sectional quantiles of their Janus kinase 2 (JAK2) RNA expression levels. Sample mRNA expression of PD-L1 and mutational load, CD8A expression [representing CD8+ cytolytic T lymphocytes (CTLs)], cytolytic activity (“CYT”) expression, and viral association were compared among groups.
Results: High mRNA expression and gene amplification of PD-L1 were both significantly associated with high JAK2 expression (P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/21488}
}